Tim J. Wigle

5.6k citations

37 papers · 2.0k · 1 hit paper · h-index 22

Impact in

Molecular Biology top 5%
- Epigenetics and DNA Methylation
- Cancer-related gene regulation
- Histone Deacetylase Inhibitors Research
- Protein Degradation and Inhibitors
- RNA modifications and cancer
- Chromatin Remodeling and Cancer
- Genomics and Chromatin Dynamics
Molecular Medicine top 5%
- Antibiotic Resistance in Bacteria

Papers in

Molecular Biology 29
- Epigenetics and DNA Methylation 21
- Cancer-related gene regulation 18
- RNA modifications and cancer 10
- Histone Deacetylase Inhibitors Research 5
- Genomics and Chromatin Dynamics 5
Oncology 6
- PARP inhibition in cancer therapy 5

Co-authors: Robert A. Copeland (14 shared papers)Kevin W. Kuntz (18 shared papers)Mikel P. Moyer (11 shared papers)Margaret Porter Scott (12 shared papers)Sarah K. Knutson (9 shared papers)Heike Keilhack (12 shared papers)Victoria M. Richon (8 shared papers)Roy M. Pollock (7 shared papers)
Journals: SLAS DISCOVERY (4 papers)Journal of Medicinal Chemistry (3 papers)Cancer Research (3 papers)PLoS ONE (2 papers)Biochemistry (2 papers)
Partner nations: United States Canada Germany

In The Last Decade

Tim J. Wigle

35 papers receiving 1.9k citations

Tim J. Wigle's Hit Papers

align trajectories log scale

Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2 2013 · 589 citations

Peers

Countries citing papers authored by Tim J. Wigle

Since Specialization

Citations

This map shows the geographic impact of Tim J. Wigle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim J. Wigle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim J. Wigle more than expected).

Fields of papers citing papers by Tim J. Wigle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim J. Wigle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim J. Wigle. The network helps show where Tim J. Wigle may publish in the future.

Co-authors

The 25 scholars most cited alongside Tim J. Wigle, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Tim J. Wigle Line = papers co-authored together Tim J. Wigle links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 37 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2 Proceedings of the National Academy of Sciences ·Sarah K. Knutson, Natalie M. Warholic, Tim J. Wigle, Christine R. Klaus, Christina J. Allain, Alejandra Raimondi, Margaret Porter Scott, Richard Chesworth, Mikel P. Moyer, Robert A. Copeland, Victoria M. Richon, Roy M. Pollock, Kevin W. Kuntz, Heike Keilhack Hit paper breakdown →	2013	589
2	The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat Journal of Medicinal Chemistry ·Kevin W. Kuntz, John E. Campbell, Heike Keilhack, Roy M. Pollock, Sarah K. Knutson, Margaret Porter-Scott, Victoria M. Richon, Chris Sneeringer, Tim J. Wigle, Christina J. Allain, Christina R. Majer, Mikel P. Moyer, Robert A. Copeland, Richard Chesworth	2016	129
3	Conformational Adaptation Drives Potent, Selective and Durable Inhibition of the Human Protein Methyltransferase DOT1L Chemical Biology & Drug Design ·Aravind Basavapathruni, Lei Jin, Scott R. Daigle, Christina R. Majer, Carly A. Therkelsen, Tim J. Wigle, Kevin W. Kuntz, Richard Chesworth, Roy M. Pollock, Margaret Porter Scott, Mikel P. Moyer, Victoria M. Richon, Robert A. Copeland, Edward J. Olhava	2012	116
4	A687V EZH2 is a gain‐of‐function mutation found in lymphoma patients FEBS Letters ·Christina R. Majer, Lei Jin, Margaret Porter Scott, Sarah K. Knutson, Kevin W. Kuntz, Heike Keilhack, J. Joshua Smith, Mikel P. Moyer, Victoria M. Richon, Robert A. Copeland, Tim J. Wigle	2012	116
5	EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity ACS Medicinal Chemistry Letters ·John E. Campbell, Kevin W. Kuntz, Sarah K. Knutson, Natalie M. Warholic, Heike Keilhack, Tim J. Wigle, Alejandra Raimondi, Christine R. Klaus, Nathalie Rioux, Akira Yokoi, Satoshi Kawano, Yukinori Minoshima, Hyeong-Wook Choi, Margaret Porter Scott, Nigel J. Waters, J. Joshua Smith, Richard Chesworth, Mikel P. Moyer, Robert A. Copeland	2015	97
6	Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound ACS Medicinal Chemistry Letters ·Lorna H. Mitchell, Allison E. Drew, Scott Ribich, Nathalie Rioux, Kerren K. Swinger, Suzanne L. Jacques, Trupti Lingaraj, P. Ann Boriack‐Sjodin, Nigel J. Waters, Tim J. Wigle, Oscar Moradei, Lei Jin, (unknown), Margaret Porter-Scott, Mikel P. Moyer, J. Joshua Smith, Richard Chesworth, Robert A. Copeland	2015	95
7	Small-Molecule Ligands of Methyl-Lysine Binding Proteins Journal of Medicinal Chemistry ·J. Martin Herold, Tim J. Wigle, Jacqueline L. Norris, Robert Lam, Victoria Korboukh, Cen Gao, Lindsey A. Ingerman, Dmitri Kireev, Guillermo Senisterra, Masoud Vedadi, Ashutosh Tripathy, Peter J. Brown, C.H. Arrowsmith, Jian Jin, William P. Janzen, Stephen V. Frye	2011	92
8	Screening for Inhibitors of Low-Affinity Epigenetic Peptide-Protein Interactions: An AlphaScreen™-Based Assay for Antagonists of Methyl-Lysine Binding Proteins SLAS DISCOVERY ·Tim J. Wigle, J. Martin Herold, Guillermo Senisterra, Masoud Vedadi, Dmitri Kireev, C.H. Arrowsmith, Stephen V. Frye, William P. Janzen	2009	65
9	The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states FEBS Letters ·Tim J. Wigle, Sarah K. Knutson, Lei Jin, Kevin W. Kuntz, Roy M. Pollock, Victoria M. Richon, Robert A. Copeland, Margaret Porter Scott	2011	62
10	Directed molecular screening for RecA ATPase inhibitors Bioorganic & Medicinal Chemistry Letters ·Tim J. Wigle, Scott F. Singleton	2007	61
11	Novel Inhibitors of E. coli RecA ATPase Activity PubMed ·Jonathan Z. Sexton, Tim J. Wigle, Qingping He, Mark Hughes, Ginger R. Smith, Scott F. Singleton, Alfred L. Williams, Li-An Yeh	2010	57
12	Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas PLoS ONE ·Sarah K. Knutson, Natalie M. Warholic, L. Danielle Johnston, Christine R. Klaus, Tim J. Wigle, Dorothy Iwanowicz, Bruce A. Littlefield, Margaret Porter-Scott, J. Joshua Smith, Mikel P. Moyer, Robert A. Copeland, Roy M. Pollock, Kevin W. Kuntz, Alejandra Raimondi, Heike Keilhack	2014	55
13	Inhibitors of RecA Activity Discovered by High-Throughput Screening: Cell-Permeable Small Molecules Attenuate the SOS Response in Escherichia coli SLAS DISCOVERY ·Tim J. Wigle, Jonathan Z. Sexton, Anna V. Gromova, Mallinath B. Hadimani, Mark Hughes, Ginger R. Smith, Li-An Yeh, Scott F. Singleton	2009	49
14	Enabling drug discovery for the PARP protein family through the detection of mono-ADP-ribosylation Biochemical Pharmacology ·Alvin Lu, Ryan Abo, Yue Ren, Bin Gui, Jan-Rung Mo, Danielle J. Blackwell, Tim J. Wigle, Heike Keilhack, Mario Niepel	2019	39
15	Identification of Non-Peptide Malignant Brain Tumor (MBT) Repeat Antagonists by Virtual Screening of Commercially Available Compounds Journal of Medicinal Chemistry ·Dmitri Kireev, Tim J. Wigle, Jacqueline Norris‐Drouin, J. Martin Herold, William P. Janzen, Stephen V. Frye	2010	38
16	Accessing Protein Methyltransferase and Demethylase Enzymology Using Microfluidic Capillary Electrophoresis Chemistry & Biology ·Tim J. Wigle, Laurel M. Provencher, Jacqueline L. Norris, Jian Jin, Peter J. Brown, Stephen V. Frye, William P. Janzen	2010	37
17	A High-Throughput Mass Spectrometry Assay Coupled with Redox Activity Testing Reduces Artifacts and False Positives in Lysine Demethylase Screening SLAS DISCOVERY ·Tim J. Wigle, Kerren K. Swinger, John E. Campbell, Michael D. Scholle, John Sherrill, Elizabeth A. Admirand, P. Ann Boriack‐Sjodin, Kevin W. Kuntz, Richard Chesworth, Mikel P. Moyer, Margaret Porter Scott, Robert A. Copeland	2015	31
18	Epigenetics: tools and technologies Drug Discovery Today Technologies ·William P. Janzen, Tim J. Wigle, Jian Jin, Stephen V. Frye	2010	29
19	Reaction Coupling between Wild-Type and Disease-Associated Mutant EZH2 ACS Chemical Biology ·Brooke M. Swalm, Sarah K. Knutson, Natalie M. Warholic, Lei Jin, Kevin W. Kuntz, Heike Keilhack, J. Joshua Smith, Roy M. Pollock, Mikel P. Moyer, Margaret Porter Scott, Robert A. Copeland, Tim J. Wigle	2014	27
20	Biophysical Probes Reveal a “Compromise” Nature of the Methyl-lysine Binding Pocket in L3MBTL1 Journal of the American Chemical Society ·Cen Gao, J. Martin Herold, Dmitri Kireev, Tim J. Wigle, Jacqueline L. Norris, Stephen V. Frye	2011	25

About Tim J. Wigle

Tim J. Wigle is a scholar working on Molecular Biology, Oncology, Genetics, Molecular Medicine and Electrical and Electronic Engineering, having authored 37 papers that have together received 2.0k indexed citations. Recurring topics across this work include Epigenetics and DNA Methylation (21 papers), Cancer-related gene regulation (18 papers), RNA modifications and cancer (10 papers), PARP inhibition in cancer therapy (5 papers), Histone Deacetylase Inhibitors Research (5 papers), Genomics and Chromatin Dynamics (5 papers), Integrated Circuits and Semiconductor Failure Analysis (4 papers) and Antibiotic Resistance in Bacteria (4 papers). The work is most often cited by research in Molecular Biology (1.6k citations), Molecular Medicine (96 citations), Oncology (201 citations), Pathology and Forensic Medicine (123 citations) and Hematology (70 citations). Tim J. Wigle has collaborated with scholars based in United States, Canada and Germany. Frequent co-authors include Robert A. Copeland, Kevin W. Kuntz, Mikel P. Moyer, Margaret Porter Scott, Sarah K. Knutson, Heike Keilhack, Victoria M. Richon, Roy M. Pollock, Richard Chesworth and Scott F. Singleton. Their work appears in journals such as SLAS DISCOVERY, Journal of Medicinal Chemistry, Cancer Research, PLoS ONE and Biochemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Tim J. Wigle

Impact in

Papers in i

In The Last Decade

Tim J. Wigle

Tim J. Wigle's Hit Papers

Peers

Countries citing papers authored by Tim J. Wigle

Fields of papers citing papers by Tim J. Wigle

All Works

About Tim J. Wigle

Explore authors with similar magnitude of impact

Papers in